One reason for this enhanced efficacy may be that the targeted particles are designed to bind to the galectins Gal-1, Gal-3, Gal-4 proteins on pancreatic cancer cells or galectin-rich tumor-stroma, thus possibly delaying clearance from the site of the tumor. The gene discussed is LGALS4; the disease is neoplasm.